Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.59 |
| ▸ | MAPT | P10636 | 4/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | HPGD | P15428 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 3/20 | 0.42 |
| ▸ | PI4KA | P42356 | 3/20 | 0.38 |
| ▸ | PI4K2B | Q8TCG2 | 3/20 | 0.38 |
| ▸ | PI4K2A | Q9BTU6 | 3/20 | 0.38 |
| ▸ | PI4KB | Q9UBF8 | 3/20 | 0.38 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.37 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.37 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.37 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.37 |
| ▸ | ABL1 | P00519 | 1/20 | 0.37 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.37 |
| ▸ | LCK | P06239 | 1/20 | 0.37 |
| ▸ | CSF1R | P07333 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5244234 | 0.90 | LMNA (0.56) | LMNAMAPTSMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL21611531 | 0.78 | MAPT (0.46) | LMNAMAPTSMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL5246745 | 0.71 | LMNA (0.58) | LMNAMAPTSMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL5247221 | 0.71 | NR1H2 (0.50) | LMNAMAPTSMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL5246815 | 0.71 | LMNA (0.58) | LMNAMAPTSMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL796397 | 0.68 | LMNA (0.44) | LMNAMAPTSMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL191691 | 0.68 | CDC7 (0.61) | LMNAMAPTSMN1; SMN2ALDH1A1HPGD | |
| Hydrochloric Acid SCHEMBL21611457 | 0.67 | PNP (0.49) | LMNAMAPTSMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL5132695 | 0.67 | LMNA (0.48) | LMNAMAPTSMN1; SMN2ALDH1A1PI4KA | |
| SCHEMBL11749396 | 0.67 | SMN1; SMN2 (0.43) | LMNAMAPTSMN1; SMN2ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8541406-B2 | Thiadiazole derivatives for the treatment of neurodegenerative diseases | NV REMYND (BE) | 2013-09-24 | — | — | US | disclosed |
| US-20100261707-A9 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2010-10-14 | — | — | US | disclosed |
| US-20090233911-A2 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2009-09-17 | — | — | US | disclosed |
| US-20090054410-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233911-A2 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PARK7 | LMNA 1113/4885MAPT 9/4885SMN1; SMN2 4/4885 |
| US-20100261707-A9 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PARK7 | LMNA 1113/4885MAPT 9/4885SMN1; SMN2 4/4885 |
| US-20090054410-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PARK7 | LMNA 1113/4885MAPT 9/4885SMN1; SMN2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.